January 1, 2022 – ROCK inhibitor Induces Cell Death in Melanoma Cells

Atrial Natriuretic Peptide Receptors

While cetuximab has demonstrated activity in SCCHN, new agents and treatment strategies are needed that will provide both improved tolerability and efficacy

While cetuximab has demonstrated activity in SCCHN, new agents and treatment strategies are needed that will provide both improved tolerability and efficacy. Future directions beyond cetuximab: inhibiting the ErbB family

hwupdate
January 1, 2022

Day: January 1, 2022

﻿While cetuximab has demonstrated activity in SCCHN, new agents and treatment strategies are needed that will provide both improved tolerability and efficacy

While cetuximab has demonstrated activity in SCCHN, new agents and treatment strategies are needed that will provide both improved tolerability and efficacy